OOIR: Observatory of International Research

Papers

(The TQCC of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Melatonin, metformin, and ranolazine equally improved cognitive function in rats with doxorubicin‐induced chemobrain	2311
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats	1753
	1115
Issue Information	1045
	583
RBFOX1 is regulated by the adenosine 2a receptor and is ubiquitinated in tau tangles in Alzheimer’s disease	409
The Relationship of Neuropsychiatric Symptoms and ADRD Pathologies	313
Examination of intrapersonal and affective characteristics associated with everyday function among older adults with subjective cognitive decline	311
Heterogeneous clinical phenotypes of sporadic Early‐onset Alzheimer’s disease: A data‐driven approach	273
Effects of lifestyle factors on Alzheimer’s disease symptoms in adults with Down syndrome	191
	184
Cognitive Disparities in the Wayuu Indigenous Population: Insights from Neuropsychological Assessment	176
The modified Rowland Universal Dementia Assessment Scale for dementia screening in Peruvian population	174
Cognitive performance in individuals aged 80 or over from south of Brazil	172
Association between pulmonary function and cognition in urban Indian adults – A cross sectional analysis	160
Usability of a Self‐Administered Cognitive Assessment in Patients with Progressive Supranuclear Palsy and Correlation with Traditional Neuropsychological Tests: A Mayo Test Drive Pilot Study	157
Utility of two computerized assessments for predicting clinical progression in individuals with early Alzheimer’s Disease	153
Assessing Short‐term Memory with Different Memory Modalities in Mild Cognitive Impairment	151
Association of CSF AD biomakers and lifestyle factors with neuropsychiatric symptoms among non‐demented older persons	142
Cognitive Complaint, Mild Cognitive Impairment, and Mild Behavioral Impairment as Predictors of Dementia or Alzheimer’s Disease in a Population‐Based Sample: The Cache County Study	142
Comparing the Brief Assessment of Cognitive Health and Montreal Cognitive Assessment: Test‐retest reliability and sensitivity to cognitive change in older adults	130
Aberrant resting‐state functional connectivity of the default‐mode network relates to cognitive decline in the earliest Alzheimer’s continuum	130
Passively collected smartphone behaviour as a reliable and feasible measure for global cognition in Alzheimer’s Disease	127
Deep learning‐based estimation of future brain atrophy using baseline MRI and PET	120
Intracranial atherosclerosis is linked to lower volume in the posterior portion of the hippocampus	119

Contrast of Early Phase Amyloid PET	106
Plasma and neuroimaging biomarkers of small vessel disease and Alzheimer’s disease in a diverse cohort	104
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	98
Synapse loss in early‐ and late‐onset Alzheimer’s Disease assessed by 18F‐SynVest‐1	97
Myelin water imaging with clinically feasible scan time: the accelerated BMC‐mcDESPOT (aBMC‐mcDESPOT) method	96
Standardizing Care for Agitation in Alzheimer’ Dementia: Results from a Randomized Controlled Trial of an Integrated Care Pathway versus Usual Care ‐The StaN trial	94
Reframing motherhood in dementia research: A call for action	91
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	88
	83
Cognitive aging outcomes are related to both tau pathology and maintenance of cingulate cortex structure	82
Analysis of the ACE‐R’s sub‐items that best differentiate healthy controls, amnestic MCI and non‐amnestic MCI	79
Prevalence of neuropsychiatric conditions and cognitive impairment in two parallel, aging study cohorts from rural and urban India	79
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium	77
Characterizing accelerated long‐term forgetting in preclinical Alzheimer’s disease using the Boston Remote Assessment for NeuroCognitive Health (BRANCH)	76
Short‐term Sirolimus Treatment Restores Hippocampus and Caudate Volumes and Global Cerebral Blood Flow in Asymptomatic APOE4 Carriers Compared with Non‐carriers	74
Education, neighborhood environment, and cognitive decline: Findings from two prospective cohort studies of older adults in China	73
FDA‐approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness	73
Optimized ACI‐24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and Pyroglutamate Abeta, key pathological species of Alzheimer’s disease (AD)	70
Developing machine‐learning‐based amyloidogenicity predictors with Cross‐Beta DB	70
Mendelian randomization highlights causal association between genetically increased C‐reactive protein levels and reduced Alzheimer's disease risk	69
Dementias Platform UK: Bringing genetics into life	69
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study	69
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease	69
Dissipating the fog: Cognitive trajectories and risk factors 1 year after COVID‐19 hospitalization	68
Decentralized clinical trials for medications to reduce the risk of dementia: Consensus report and guidance	68
Subjective cognitive decline across ethnoracial groups in the A4 study	67
The association between cardiorespiratory fitness and resting‐state functional connectivity in adults with Down syndrome	66
Lithium carbonate treatment decrease neuroinflammation and ameliorates long‐term memory in a Down syndrome animal model	65
Association of neighborhood socioeconomic disadvantage and cognitive decline	65
Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years	64
Amyloid‐Beta PET Synthesis from Structural MRI: A Potential Alternative Method for Alzheimer’s Disease Screening	64
Racial disparities in Alzheimer’s Disease (AD): Correlating a novel neuropsychological screening test to established AD fluid and imaging biomarkers in African Americans and Caucasians	64
A head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic	64
Weight loss and risk of dementia in individuals with versus without obesity	63
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy	63
Program of intensive support in emergency departments for care partners of cognitively impaired patients: A randomized controlled trial	62
Dual‐stream algorithms for dementia detection: Harnessing structured and unstructured electronic health record data, a novel approach to prevalence estimation	62
Mild kidney dysfunction affects the predictive accuracy of blood‐based biomarkers for neuropsychological and neuroimaging outcomes over a 9 year follow‐up period	62
Integrated analysis of in vivo retinal perivascular amyloid imaging and cognition	61
Longitudinal neuropsychological evaluation allows diagnosis of MCI with less severe memory change	61
Correction to “Using remote, digital, multi‐day testing to characterize long‐term forgetting in cognitively unimpaired older adults”	58
The Global Neurodegeneration Proteomics Consortium ‐ Biomarker and Drug Target Discovery Across >40,000 Biosamples for AD, PD, ALS, FTD, and Aging	57
Associations of hippocampal cholinergic receptor binding and subcortical cerebrovascular disease with whole brain volume in cognitive aging and AD	56
Large‐scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease	56
Trajectories of cognitive decline and dementia development: A 12‐year longitudinal study	56
Evaluation of Two Plasma pTau217 Simoa Assays Against Amyloid‐PET	55
Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease	55
The moderating effect of APOE E4 on the association of plasma biomarkers with markers of cognition and brain health in Alzheimer’s disease	54
Comparative Toxicogenomics Database: A tool to investigate the effects of environmental exposures on the etiology of Alzheimer’s disease	53
A brain atlas of astrocyte transcriptomics unveils complex states and responses to Alzheimer’s disease neuropathology	53

Cerebral Small Vessel Disease and Gait Speed in Older Adults without Dementia	53
Interneuron hyperexcitability in an APP/PS1 mouse model of Alzheimer’s disease	53
Recruitment data of the HAPPCAP‐AD (Human‐APPlication Combined Approach for Prevention of Alzheimer’s Disease): a feasibility study	52
Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	52
Seizures exacerbate tau spread in the 5XFAD mouse model	52
Developing a preference‐based quality of life for people living with dementia in Vietnam	52
Bridging the Gap: The Global CEOi Collaborative Workgroup for Adoption of Alzheimer’s disease Blood‐Based Biomarkers in Clinical Practice	51
A Rule‐Based Framework to Identify Severity of Dementia from Unstructured Electronic Health Record Data	51
Antagonistic Amyloid‐β and tau interactions with T1‐weighted/T2‐weighted magnetic resonance ratio in Alzheimer’s disesase continuum	50
Advanced measures of cortical microstructural change and associations with cognitive and blood‐based biomarkers in autosomal dominant Alzheimer’s disease	50
Mechanisms Mediating the Anti‐inflammatory Effects of Eicosapentaenoic Acid in the APPswePS1dE9 Alzheimer's Mouse Model	50
Transition in the cognitive continuum from normal cognition to dementia: the interplay of lifelong cognitive reserve with brain aging and genetic predisposition	50
Comparison of histological delineation of the entorhinal, perirhinal, ectorhinal, and parahippocampal cortices by different neuroanatomy laboratories	49
Baseline Frailty and Domain‐specific Cognitive Declines in Healthy and MCI Older Adults	48
Validated, unified theory of Alzheimer Disease illuminates two essential research questions	48
White matter hyperintensities: A long‐term consequence of repetitive head impacts?	48
Assessment of ccf‐Mitochondrial DNA Damage in Cognitive Impairment via NGS: Health Disparities in Mexican Americans	48
Loss of apolipoprotein E exacerbates microglial and astrocyte reactivity to sustained systemic glucocerebrosidase inhibition	48
Modifiable dementia risk factor associations with AT(N) biomarkers: Findings from the European Prevention of Alzheimer’s Dementia study	47
Clinically relevant monitoring of long‐term night‐time behaviour and physiology from the homes of people living with dementia	47
A retinal tauopathy with a characteristic molecular pattern points to the existence of a “Primary retinal tauopathy”	47
Evaluating the use of eye tracking tasks as language‐ and culturally‐neutral assessments of cognition in a multi‐ethnic cohort of older adults	46
The App^NL‐G‐F/MAPT mouse model of Alzheimer’s Disease demonstrates increased levels of ptau217 in CSF, changes that correlate with increased cerebral p‐tau depositions	46
The atrophy of specific amygdala subnuclei is associated with temporal tauopathy in preclinical AD individuals	46
Reduced density of serotonergic axons without prominent neuron loss or tau pathology in the dorsal raphe nucleus in App knock‐in mouse models of amyloid‐β pathology	46
Putative Cellular Identity of Dystrophic Neurites in FTLD‐TDP Type C	46
Integrated Primary Care Model Prevents Hospitalizations for People Living with Dementia	46
APOE loss‐of‐function variants: Compatible with longevity and associated with resistance to Alzheimer’s Disease pathology	45
A portable eye tracking experiment for the assessment of cognitive impairment in presymptomatic frontotemporal dementia	45
The potential protective benefit of personality on subjective cognitive decline related worry: Results from the Canadian Longitudinal Study on Aging (CLSA)	45
Prevalence of risk factors for dementia and association with cognitive alterations in an elderly population from the South of Brazil	45
How well is Brazil prepared for a disease‐modifying Alzheimer’s treatment?	45
NEUROPROTECTIVE EFFECT OF PERILLYL ALCOHOL IN EXPERIMENTAL SPORADIC AD	45
Syzigium aromaticum may protect against paraquat mediated toxicity via p53 and Sestrin2 modulation	45
Non‐Invasive Temporal Interference Hippocampal Stimulation in Early Alzheimer’s Disease	44
Do the extracellular vesicles excreted during neuronal cell death play a neuron‐glia signalling role in neurodegeneration.	44
The association between air pollution and dementia: results from the Cognitive Function and Ageing Study II and Wales	43
Association of the learning ratio with AD biomarkers after application of actuarial diagnostic criteria to ADNI cognitively normal participants	43
Exploring Narrative Identity via Linguistic Positioning in the Context of Alzheimer’s Dementia Risk Prediction – an Ethical and Linguistic Analysis	43
Multiple pathological mechanisms of Bin1 for tau aggregation and propagation	43
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum	43
The role of impaired oxidative base lesion repair in Alzheimer’s disease	43
Longitudinal patterns of behavioral and psychological symptoms of dementia in community‐dwelling older people	42
Iron–induced, sex‐specific alterations of mitochondrial bioenergetic function and increased amyloid beta plaque size in 5xFAD mice	42
The Influence of Prior Head Injury on Late‐Life Cognition and White Matter Microstructure in Older Adults At‐Risk of Alzheimer’s disease	42
A Drosophila ortholog of Toll‐like receptors modulates c‐Jun N‐terminal kinase signaling and protects against tau‐mediated neurodegeneration independent of innate immune response	42
Widespread transposable element dysregulation in human brains with Alzheimer’s disease	42
Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case‐control study using Dutch primary care data	42
Movement with Dementia: A feasibility study of a resource to support the personalisation of therapeutic exercise programmes for people living with dementia	42
Synthetic FDG‐PET hypometabolism sensitivity validation in AD	42
TREM2 Burden associates solely with Alzheimer’s Disease, and decreases the Chance to become a Centenarian	42
Glial and synaptic biomarkers as early indicators of mild cognitive decline	42
Reconsideration of appropriate use criteria for amyloid PET based on real‐world experiences	41
Preserved transcriptional networks in immune signaling pathways associated with chronic disease identified in Alzheimer’s disease and Parkinson’s disease, cross‐tissue analysis	41
The real‐world implementation strategies for plasma p‐tau217 in tertiary care memory clinics in Thailand	41
A Machine Learning Approach to Identify Individualized Baseline MRI, Plasma, Cardiovascular and Lifestyle Predictors of a 5‐Year Cognitive Decline	41
Amyloid β‐dependent tau phosphorylation is triggered by reactive astrocytes in preclinical Alzheimer’s disease	41
Analytical Choices of Timescale in the Presence of Practice and Cohort Effects in Longitudinal Cognitive Aging Research: A Simulation Study Using Linear Mixed‐Effects Models	41
Baseline characteristics of INTERCEPT‐AD: A phase 1 trial with ACU193 targeting soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease	40
Amyloid and Tau Predominance Subtyping Identifies CI Patients With Different Clinical Phenotypes	40
Exploring biomarker profiles of the cognitively unimpaired individuals in early tau PET Braak stage	40
Alzheimer’s disease specific MRI brain regions are differentially associated with accelerated decline as defined using sigmoidal cognitive turning point methodology in amyloid‐positive AIBL participan	40
Proteomics identification of novel proteins dysregulated in Alzheimer’s Disease with potential as blood‐based biomarkers and related to Amyloid‐Beta Plaques	40
Cognitive Impairment in Firefighters and Emergency Medical Services Workers after Severe WTC Exposures	39
Pupillometry as a marker of arousal and in relation to cognition and cortical dynamics in Alzheimer’s disease	39
Simian varicella virus infection in rhesus macaques is associated with amyloid deposition in multiple organs and arteries and production of an amyloidogenic state	39
The impact of subjective cognitive decline on aging effects in the brain as measured by diffusion tensor imaging	39
The Association between the Body Fat Localization, Insulin Resistance, and Amyloid Burden in Midlife	38
Comparative efficacy of cholinesterase inhibitors and memantine on cognition in AD patients with application of network meta‐analysis	38
Associations between blood‐based biomarkers and other outcomes related to Alzheimer’s disease	38
Diffusion MRI subnetwork efficiency is associated with cognitive resilience to AD pathology in cognitively unimpaired older adults at risk of AD dementia	38
Applying novel EMBRACE technological solutions to measure and optimize brain response to exercise.	38
A predictive regression model for mild cognitive impairment and Alzheimer´s disease using real‐world electronic health records	38
A cluster randomized trial: Exploratory quantitative analysis comparing resident outcomes for two approaches to promote non‐pharmacological, resident‐centered dementia care in nursing homes	37
Assessment of fluid biomarker profiles across disease continuum in a non‐human primate model of sporadic CAA	37
Preliminary Evidence for the Combined Efficacy of Focused Ultrasound Blood‐Brain Barrier Opening and Delivery of a Novel Anti‐Amyloid Re Complex for Memory Improvement in a 3xTg‐Alzheimer’s Disease Mo	37
The relationship between cortical grey to white matter signal contrast (GWC) and tau pathology in atypical AD	37
Ethnic Disparities in Clinical Presentation of Patients with Early‐Onset Alzheimer’s Disease	37
2021 Annual Report of Japanese Brain Bank Network for Neuroscience Research	37
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	36

Exploring Social Engagement in a Virtual Participatory Culinary Nutrition Education Intervention for Dementia Prevention	36
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population	36
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults	36
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging	35
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults	35
Is QEEG an effective biomarker in predicting cognitive decline?	35
The association of gait velocity and cognitive performance in a sample of older Chinese Americans: A pilot study	35
Prediction of amyloid‐beta accumulating normal cognitive elderly	35
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians	35
Characterizing amyloid positive individuals with normal tau PET levels five years later: An ADNI study	35
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints	35
The impact of the COVID‐19 pandemic on cognitive health	34
Transgender adults report greater cognitive and related functional challenges: Findings from the 2015‐2019 Behavioral Risk Factor Surveillance System	34
Rural/Urban Disparities in PQIs Among Patients with ADRD – Evidence of Hospital‐based HIT and Enabling Services	34
Technical performance and biotemporal stability evaluation of Olink proximity extension assay for blood‐based biomarker discovery	34
Ancestry‐Specific eQTL Associations in AA/NHW Alzheimer Disease Cohorts	34
The troubles and needs of family caregivers of older adults with moderate to severe dementia	34
Hyperintensity on Diffusion‐Weighted MRI and Clinical Correlations in Probable Creutzfeldt‐Jakob Disease	34
Depression in Alzheimer’s disease hospitalized patients: A descriptive analysis of a nationwide database	34
Quantitative amyloid PET in the AMYPAD diagnostic and patient management study	34
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	34
Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum	34
Associations of sleep disturbances with cognitive function and plasma Alzheimer’s biomarkers in Chinese rural‐dwelling older adults: A population‐based study	34
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network	33
Association of Epigenetic Aging with Cognitive Aging in Diverse Hispanics/Latinos	33
Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)	33
Testamentary Capacity Assessment Tool (TCAT): An update report	33
Explainable AI and its instantiation in Computational Pathology for a better understanding of Alzheimer’s disease	33
A comprehensive literature search of digital health technology use in dementia: Digital tools to support dementia caregivers	33
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	33
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	33
Impaired retinal capillary function in patients with clinical Alzheimer’s disease	33
Systemic and central nervous system metabolome changes associated with Ginkgo biloba treatment in non‐demented subjects	32
Decline in cognitive trajectories in the neuropathological spectrum of Lewy Body disease	32
Ameliorative effects of Aqueous Fruit Pulp Extracts of Adansonia digitata on the Hippocampus of Aluminium Chloride‐treated Adult Wistar Rats	32
Theta‐Gamma Phase‐Amplitude Coupling Deficit in Streptozotocin AD Rat Model	32
Elderly Role Performance Occupational Therapy	32
Improving Early Detection of White Matter Degeneration in Aging and Dementia along the AD continuum	32
Association of air quality reduction with incident dementia: Effects of natural course and hypothetical air pollutant interventions using g‐computation	32
Language, cognitive and neuroimaging determinants of Primary Progressive Aphasia in Hebrew Speakers, a case series	32
A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ)	32
Comparison of remote and in‐person digital speech‐based measures of cognition	32
Plasma GFAP:NfL discriminates FTLD‐tau from FTLD‐TDP	31
Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe	31
Cardiorespiratory fitness is an important marker of cognitive performance in older Latin Americans	31
Bibliographic Analysis of Aging Anxiety and Lifestyle	31
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	31
Outreach and recruitment of African Americans for Alzheimer’s disease studies during the COVID‐19 pandemic	31
Experiences of People Living with Dementia and their Care Partners in Participating in Outdoor Activities	31
A 10‐minute Digitally Administered and Scored Neuropsychological Protocol Assessing Executive Control and Episodic Memory	31
The effect of virtual reality and physical exercise training on cognitive function in older adults with mild cognitive impairment	30
Microvascular Morphology MR Imaging Using Relaxation Rate Change with Gadolinium‐Based Contrast Agent in Patients with Alzheimer’s Disease	30
Characteristics of peripheral immune system in a novel App^NL‐G‐F knock‐in mouse model of Alzheimer’s disease	30
Cerebellar‐cortical functional connectivity is associated with Alzheimer’s disease pathology and cerebellar atrophy	30
Cognitive correlations with amyloid, tau and neurodegeneration PET across the Alzheimer’s disease age spectrum	30
Dementia‐inclusive radio series ‘Talkin’ About Neurodegeneration'—A look under the dementia umbrella and a follow‐on series to award‐winning ‘Voyage Around My Brain’ on NearFM	30
Usability experience of remote sleep monitoring in patients with neurodegenerative diseases	30
Recognizing human functional patterns in IADLs through hand detection and artificial intelligence	30
Cerebral perfusion and amyloidosis in the oldest‐old	30
Association between ¹⁸F – FDG uptake and global cognitive performance in individuals at risk of dementia	29
Assessment of apathy‐like behaviour in transgenic mouse models of neurodegenerative diseases	29
TMS‐based measures of cortical excitability are related to distributed atrophy in early Alzheimer’s disease	29
Impact of left censoring on longitudinal analyses of dementia using electronic health record data	29
Inflammation and working memory performance in everyday life: Gender differences among older adults with and without cognitive impairment	29
A Study of Factors Influencing Quality of Life among Community Dwelling Elderly in Korean Urban Community	29
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	29
CASBA neurological assessment: Noninvasive EEG biomarkers classify amyloid‐PET, clinical diagnosis, cognitive dementia rating, and FCSRT free recall scores in patients with cognitive decline	29
What attributes have been included in discrete choice experiments related to health technologies used in the early detection, diagnosis and treatment of neurodegenerative conditions? A systematic lite	29
Hypogyrification in midlife women with surgical menopause, a population at risk for late life Alzheimer’s	29
High Social Deprivation as a Risk Factor for Dementia: Findings from the longitudinal SHARE study of older Europeans	29
Exploring the role of brain DNA methylomic signatures on gene expression dynamics of frontotemporal lobar degeneration	28
Methods in Prioritizing Pathways and Targets from Expression Data	28
Exploring the basis of phenotypic diversity in Alzheimer’s disease	28
Single‐nucleus RNAseq‐derived pseudo‐temporal modeling of neurodegeneration in astrocytes of older brains	28
Comparison of Vascular Health in Super‐Agers and Cognitively Normal Adults 80 Years and Older	28
Differential Effects of Anticholinergic Medications in a Human Neuronal Model of AD	28
The Aging Brain Clinic (ABC): An innovative model for managing patients with mild cognitive impairment	28
Machine learning algorithm selects transcripts in blood to distinguish Alzheimer’s disease and other neurodegenerative diseases	28
Positive association of Cerebral Amyloid Angiopathy (CAA) with R2 Relaxation rate: A study of ex‐vivo MRI and pathology	28
Resistance and resilience to Alzheimer’s disease pathology associated with lower severity of other neuropathologic diseases	28
Decline in everyday functioning in relation to cerebral tau burden across the clinical spectrum of Alzheimer’s disease	28
Resistance, brain and cognitive resilience to ATN in a memory clinic population	27
Plasma biomarker and neuroimaging changes in a Chinese community aging cohort: The Greater‐Bay‐Area Healthy Aging Brain Study (GHABS)	27
Cerebrovascular injury markers explain the effect of systemic vascular risk on cognitive decline in older adults with lower amyloid burden	27
Reproductive health data and its relationship to baseline brain imaging and cognitive measurements in cognitively unimpaired female PSEN1 E280A mutation carriers and non‐carriers from the API ADAD Tri	27
Short antibiotic treatment followed by regular administration of acid suppressant (proton pump inhibitor) reduce AB42 load in the brain and in the gut.	27
Multimodal MRI and tau PET findings from the Autosomal Dominant Alzheimer’s disease cohort caused by the A431E PSEN1 Jalisco mutation	27
Differential roles of ApoE isoforms in regulation of inflammatory cytokine expression	27
Characterization of a mouse model as a predictive tool for human Post‐Acute Sequelae of Covid‐19	27
Locus coeruleus hyperactivity in middle age may be associated with better cognitive performance	27
Lipopolysaccharide aggravates depressive‐like behavior via increasing microglial inflammation, decreasing microglial ramification, and altering tryptophan level in obese rats	27
Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial	27
Neuroprotective Potential of Limonene in LPS induced Parkinson’s Disease in Rats	27
EEG microstates as a “real time” feedback for rTMS treatment efficacy in MCI subjects	27
Associations between CSF proteins and medial temporal lobe atrophy across the AD continuum	27